Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Olsztyn – page 18

316 clinical trials in Olsztyn, Poland across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Olsztyn at a glance
316
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

316 trials in Olsztyn

Open in trial search

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Chiesi Farmaceutici S.p.A.

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Qilu Pharmaceutical Co. Ltd.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Olsztyn

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on acute myeloid leukemia treatments and innovative therapies for various types of lung cancer. Studies include evaluation of new drug combinations and treatment approaches for colorectal cancer and lymphoma.

  • Advanced treatment combinations for leukemia
  • Targeted therapies for NSCLC
  • Novel approaches in lymphoma treatment

Research emphasizes personalized medicine approaches and improving patient outcomes in advanced stages of disease.

02 Dermatology Studies

Innovative research into plaque psoriasis and psoriatic arthritis treatments, including new biological therapies and novel drug combinations. Studies also examine treatments for rare conditions like pyoderma gangrenosum.

  • Biological therapy assessment
  • Chronic skin condition management
  • Combined treatment approaches

Focus on developing more effective treatments for moderate to severe skin conditions.

03 Cardiovascular Research

Studies examining new approaches to heart failure prevention and treatment, including investigations of novel drug combinations. Research focuses on reducing cardiovascular events and improving outcomes in high-risk patients.

  • Heart failure prevention strategies
  • Cardiovascular risk reduction
  • Therapeutic combinations

Emphasis on preventive measures and innovative treatment strategies for cardiac conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.